WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Arrest Lord Mountbatten's self
Trump film shocks Cannes as former US President is depicted 'raping' his then
Abbey Clancy, 38, shows off a new set of train track braces as she's left red
David Ortiz is humbled by being honored in New York again; this time for post
Trump film shocks Cannes as former US President is depicted 'raping' his then
Should you claim child benefit? What it's worth
Ben Whishaw lights up the Croisette as he joins his co
UN Security Council rejects Russia
National Television Awards 2024 nominations: Michelle Keegan and Leo Woodall go head
Online reading or offline clubs? Young Chinese embrace both in digital era